Synthesis of self-immolative glucuronide spacers based on aminomethylcarbamate. Application to 5-fluorouracil prodrugs for antibody-directed enzyme prodrug therapy

被引:45
作者
Madec-Lougerstay, R [1 ]
Florent, JC [1 ]
Monneret, C [1 ]
机构
[1] Inst Curie, CNRS, UMR 176, Sect Rech, F-75248 Paris 05, France
来源
JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 1 | 1999年 / 10期
关键词
D O I
10.1039/a808915i
中图分类号
O62 [有机化学];
学科分类号
070303 ; 081704 ;
摘要
The synthesis of three novel potential glucuronide-based prodrugs for antibody-directed enzyme prodrug therapy (ADEPT) is described. These prodrugs were designed to be activated at the tumour site by beta-glucuronidase to afford the corresponding anticancer agent, 5-FU. The structural pattern of these compounds includes a self-immolative spacer between the glucuronyl residue and the N-1 of 5-FU. Three types of spacers have been elaborated which, after enzymic hydrolysis, spontaneously decompose to deliver an unstable N-1 aminal 5-FU derivative and, from there, the cytotoxic drug. All potential prodrugs were stable and proved to be excellent substrates of E. coli in in vitro experiments.
引用
收藏
页码:1369 / 1375
页数:7
相关论文
共 17 条
[1]   CONVERSION OF SERINE AND THREONINE RESIDUES INTO ALPHA-ACYLOXY-HALOGENOGLYCINE, ALPHA-ALKYLTHIO-HALOGENOGLYCINE, AND ALPHA-HALOGENOGLYCINE MOIETIES - A NEW STRATEGY FOR THE MODIFICATION OF PEPTIDES [J].
APITZ, G ;
STEGLICH, W .
TETRAHEDRON LETTERS, 1991, 32 (27) :3163-3166
[2]   ANTIBODY DIRECTED ENZYMES REVIVE ANTICANCER PRODRUGS CONCEPT [J].
BAGSHAWE, KD .
BRITISH JOURNAL OF CANCER, 1987, 56 (05) :531-532
[3]   THE SYNTHESIS OF ARYL-D-GLUCOPYRANOSIDURONIC ACIDS [J].
BOLLENBACK, GN ;
LONG, JW ;
BENJAMIN, DG ;
LINDQUIST, JA .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1955, 77 (12) :3310-3315
[4]   MOLECULAR AND FUNCTIONAL-CHARACTERIZATION OF A FUSION PROTEIN SUITED FOR TUMOR SPECIFIC PRODRUG ACTIVATION [J].
BOSSLET, K ;
CZECH, J ;
LORENZ, P ;
SEDLACEK, HH ;
SCHUERMANN, M ;
SEEMANN, G .
BRITISH JOURNAL OF CANCER, 1992, 65 (02) :234-238
[5]  
BOSSLET K, 1994, CANCER RES, V54, P2151
[6]  
Bosslet K, 1998, CANCER RES, V58, P1195
[7]   Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy [J].
Florent, JC ;
Dong, X ;
Gaudel, G ;
Mitaku, S ;
Monneret, C ;
Gesson, JP ;
Jacquesy, JC ;
Mondon, M ;
Renoux, B ;
Andrianomenjanahary, S ;
Michel, S ;
Koch, M ;
Tillequin, F ;
Gerken, M ;
Czech, J ;
Straub, R ;
Bosslet, K .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (19) :3572-3581
[8]  
GESSON JP, 1994, ANTI-CANCER DRUG DES, V9, P409
[9]   THE OXIDATIVE DECARBOXYLATION OF N-AROYLGLYCINES TO N-(ACETOXYMETHYL)BENZAMIDES AND N-FORMYLBENZAMIDES WITH LEAD(IV) ACETATE [J].
GLEDHILL, AP ;
MCCALL, CJ ;
THREADGILL, MD .
JOURNAL OF ORGANIC CHEMISTRY, 1986, 51 (16) :3196-3201
[10]   FLUORINATED PYRIMIDINES, A NEW CLASS OF TUMOUR-INHIBITORY COMPOUNDS [J].
HEIDELBERGER, C ;
CHAUDHURI, NK ;
DANNEBERG, P ;
MOOREN, D ;
GRIESBACH, L ;
DUSCHINSKY, R ;
SCHNITZER, RJ ;
PLEVEN, E ;
SCHEINER, J .
NATURE, 1957, 179 (4561) :663-666